Stocks
Heron Therapeutics (HRTX) EBITDA margin US GAAP (year values) |
|||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | CAGR 5 years ? | |||
| EBITDA margin, % | ? | -142.9% | -257.4% | -252.3% | -162.2% | -84.8% | -32.0% | ||
| Changes by years, y/y, % | +94pp | -114pp | +5pp | +90pp | +77pp | -18.6% | |||
Heron Therapeutics. EBITDA margin, %
Heron Therapeutics. EBITDA margin, changes, pp
Heron Therapeutics (HRTX) EBITDA margin US GAAP (quarter values) |
||||||||
| 2023Q2 | 2023Q3 | 2023Q4 | 2024Q1 | 2024Q2 | LTM ? | |||
| EBITDA margin, % | ? | -131.2% | -77.0% | -27.8% | -11.9% | -16.1% | -32.0% | |
| Changes by years, y/y, % | +46pp | +78pp | +40pp | +97pp | +115pp | |||
| Changes by quarters, q/q, % | -22pp | +54pp | +49pp | +16pp | -4pp | |||
